The stimulating effect of interleukin-33 on proliferation of the primary human lung fibroblasts
DOI:
https://doi.org/10.24959/cphj.14.1326Keywords:
interleukin-33, human lung fibroblasts, proliferationAbstract
Interleukin (IL)-33 is a multifunctional cytokine that belongs to the IL-1 cytokine family and expressed by multiple organs and cell types. Recent studies have showed that IL-33 plays an etiological role in several fibrotic disorders and may be involved in the pathogenesis of chronic respiratory diseases. It has been reported that IL-33–induced cutaneous fibrosis is associated with the increased fibroblast proliferation and altered expression of extracellular matrix-modifying genes. However, the role of IL-33 in regulating of functions of lung fibroblasts remains unclear. In the present study we examined the effect of IL-33 on proliferation of human lung fibroblasts. Five primary lines of normal adult human lung fibroblasts were cultured for 3-7 days in the presence of increasing concentrations of IL-33. We have observed that normal human lung fibroblasts responded in a dose-dependent manner to treatment with recombinant human IL-33 by increasing proliferation rates 1.5- to 2.3 fold compared to the non-stimulated control. The maximum effect of IL-33 on fibroblast proliferation was observed in the cytokine concentrations range from 2 ng/ml to 100 ng/ml. These results suggest that IL-33 may play an important role in the regulation of the human lung fibroblast proliferation. Human lung fibroblasts activated by IL-33 may act as effector cells not only in the pathogenesis of lung diseases, but also in lung remodeling processes.
References
Granne I., Southcombe J.H., Snider J.V. et аl. // PLoS One. –2011. – Vol. 6, №9. – P. 1.
Liew F.Y., Pitman N.I., McInnes I.B. // Nat. Rev. Immunol. –2010. – Vol. 10, №2. – P. 103-110.
Miller A.M. // J. Inflamm. (Lond). – 2011. – Vol. 8, №8 – P. 22.
Nabe T. // J. Pharmacol. Sci. –2014. – Vol. 126, №9.
Nishida A., Andoh A., Imaeda H. et аl. // Gut. – 2010. – Vol. 59, №4. – P. 531-541.
Oboki K., Ohno T., Kajiwara N. et аl. // Allergol. Int. – 2010. – Vol. 59, №2. – P. 143-160.
Préfontaine D., Nadigel J., Chouiali F. et аl. // J. Allergy Clin. Immunol. – 2010. – Vol. 125, №3. – P. 752-754.
Rankin A.L., Mumm J.B., Murphy E. et аl. // J. Immunol. –2010. – Vol. 184, №3. – P. 1526-1535.
Roussel L., Erard M., Cayrol C., Girard J.P. // EMBO Reports. –2008. – Vol. 9, №10. – P. 1006-1012.
Schmitz J., Owyang A., Oldham E. et аl. // Immunity. – 2005. – Vol. 23, №5. – P. 479-490.
Yamamoto T. // Self Nonself. – 2011. – Vol. 2, №1. – P. 4-10.
Downloads
Published
Issue
Section
License
Copyright (c) 2014 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
